Az AT1 angiotenzin receptorgátlás, mint új terápiás lehetóség.

Translated title of the contribution: AT1 angiotensin receptor inhibition as a new therapeutic possibility

L. Hunyady, L. Nagy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The octapeptide hormone, angiotensin II, binds to two major subtypes of cell surface receptors: the AT1 and the AT2 angiotensin receptors. The important physiological and pathophysiological effects of angiotensin II on cardiovascular regulation and salt-water balance are mediated by the AT1 receptor subtype. As a consequence of the outstanding clinical success of angiotensin-converting enzyme inhibitors, the appearance of AT1 receptor inhibitors in the therapy of hypertension and other cardiovascular diseases was preceded with great expectations. The available experimental and clinical data indicate that the first AT1 receptor inhibitor, losartan, has the same therapeutic potential as angiotensin-converting enzyme inhibitors, but it does not evoke the angiotensin-independent side-effects of ACE inhibitors, such as dry cough or angioedema. The physiological importance and the biochemical, molecular biological and pharmacological properties of AT1 and AT2 receptors are reviewed in this paper, and a summary of the available clinical data is presented.

Original languageHungarian
Pages (from-to)2583-2590
Number of pages8
JournalOrvosi Hetilap
Volume138
Issue number41
Publication statusPublished - Oct 12 1997

Fingerprint

Angiotensin Type 1 Receptor
Angiotensin-Converting Enzyme Inhibitors
Angiotensin II
Angiotensin Type 2 Receptor
Angioedema
Losartan
Angiotensins
Cell Surface Receptors
Cough
Cardiovascular Diseases
Therapeutics
Salts
Hormones
Pharmacology
Hypertension
Water

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Az AT1 angiotenzin receptorgátlás, mint új terápiás lehetóség. / Hunyady, L.; Nagy, L.

In: Orvosi Hetilap, Vol. 138, No. 41, 12.10.1997, p. 2583-2590.

Research output: Contribution to journalArticle

@article{dcb631b1c09543f5a1d248b158e210e3,
title = "Az AT1 angiotenzin receptorg{\'a}tl{\'a}s, mint {\'u}j ter{\'a}pi{\'a}s lehet{\'o}s{\'e}g.",
abstract = "The octapeptide hormone, angiotensin II, binds to two major subtypes of cell surface receptors: the AT1 and the AT2 angiotensin receptors. The important physiological and pathophysiological effects of angiotensin II on cardiovascular regulation and salt-water balance are mediated by the AT1 receptor subtype. As a consequence of the outstanding clinical success of angiotensin-converting enzyme inhibitors, the appearance of AT1 receptor inhibitors in the therapy of hypertension and other cardiovascular diseases was preceded with great expectations. The available experimental and clinical data indicate that the first AT1 receptor inhibitor, losartan, has the same therapeutic potential as angiotensin-converting enzyme inhibitors, but it does not evoke the angiotensin-independent side-effects of ACE inhibitors, such as dry cough or angioedema. The physiological importance and the biochemical, molecular biological and pharmacological properties of AT1 and AT2 receptors are reviewed in this paper, and a summary of the available clinical data is presented.",
author = "L. Hunyady and L. Nagy",
year = "1997",
month = "10",
day = "12",
language = "Hungarian",
volume = "138",
pages = "2583--2590",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "41",

}

TY - JOUR

T1 - Az AT1 angiotenzin receptorgátlás, mint új terápiás lehetóség.

AU - Hunyady, L.

AU - Nagy, L.

PY - 1997/10/12

Y1 - 1997/10/12

N2 - The octapeptide hormone, angiotensin II, binds to two major subtypes of cell surface receptors: the AT1 and the AT2 angiotensin receptors. The important physiological and pathophysiological effects of angiotensin II on cardiovascular regulation and salt-water balance are mediated by the AT1 receptor subtype. As a consequence of the outstanding clinical success of angiotensin-converting enzyme inhibitors, the appearance of AT1 receptor inhibitors in the therapy of hypertension and other cardiovascular diseases was preceded with great expectations. The available experimental and clinical data indicate that the first AT1 receptor inhibitor, losartan, has the same therapeutic potential as angiotensin-converting enzyme inhibitors, but it does not evoke the angiotensin-independent side-effects of ACE inhibitors, such as dry cough or angioedema. The physiological importance and the biochemical, molecular biological and pharmacological properties of AT1 and AT2 receptors are reviewed in this paper, and a summary of the available clinical data is presented.

AB - The octapeptide hormone, angiotensin II, binds to two major subtypes of cell surface receptors: the AT1 and the AT2 angiotensin receptors. The important physiological and pathophysiological effects of angiotensin II on cardiovascular regulation and salt-water balance are mediated by the AT1 receptor subtype. As a consequence of the outstanding clinical success of angiotensin-converting enzyme inhibitors, the appearance of AT1 receptor inhibitors in the therapy of hypertension and other cardiovascular diseases was preceded with great expectations. The available experimental and clinical data indicate that the first AT1 receptor inhibitor, losartan, has the same therapeutic potential as angiotensin-converting enzyme inhibitors, but it does not evoke the angiotensin-independent side-effects of ACE inhibitors, such as dry cough or angioedema. The physiological importance and the biochemical, molecular biological and pharmacological properties of AT1 and AT2 receptors are reviewed in this paper, and a summary of the available clinical data is presented.

UR - http://www.scopus.com/inward/record.url?scp=0031565739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031565739&partnerID=8YFLogxK

M3 - Article

C2 - 9411327

AN - SCOPUS:0031565739

VL - 138

SP - 2583

EP - 2590

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 41

ER -